

**Supplementary Table S3. Reference registry cohort of vaccinated MS patients (N=615)**

<b>Gender, N (%)</b>	
Female	460 (74.8)
Male	155 (25.2)
<b>Age at MS onset [years], median (range)</b>	30.2 (23.2–38.9)
<b>Disease duration [years], median (range)</b>	12.3 (6.4–19.6)
<b>Time to diagnosis [years], median (range)</b>	0.2 (0.0–1.9)
<b>MS disease course, N (%)</b>	
RRMS	555 (90.2)
SPMS	60 (9.8)
<b>Disability level (EDSS), N (%)</b>	
Mild (0–2.5)	371 (60.3)
Moderate (3.0–5.5)	168 (27.3)
Severe (≥6.0)	76 (12.4)
<b>DMD treatment, N (%)</b>	
High-efficacy DMD	374 (60.8)
Mild-moderate-efficacy DMD	185 (30.1)
Other DMD	3 (0.5)
DMD-untreated	53 (8.6)
<b>Relapse within the year prior to X<sup>1</sup>, N (%)</b>	50 (8.1)
<b>Time from last relapse (before X<sup>1</sup>) to X<sup>1</sup> [years], median (range)</b>	2.1 (1.0–3.3)

DMD – disease-modifying drug

EDSS – expanded disability status scale

MS – multiple sclerosis

N – number of patients

RRMS – relapsing remitting MS

SPMS – secondary progressive MS

X<sup>1</sup> – first SARS-CoV-2 vaccination